| Title |
Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, March 2018
|
| DOI | 10.1007/s00280-018-3569-9 |
| Pubmed ID | |
| Authors |
Sakura Iizumi, Atsuo Takashima, Kentaro Sakamaki, Satoshi Morita, Narikazu Boku |
| Abstract |
We conducted a systematic review and meta-analysis on survival impact of post-progression chemotherapy (post-Cx) after first-line chemotherapy (1st-Cx) and after second-line chemotherapy (2nd-Cx), and survival benefit of third-line chemotherapy (3rd-Cx) for advanced gastric cancer (AGC). Phase III trials of systemic chemotherapy for AGC published in English between 2005 and 2015 or presented at annual meetings of ASCO or ESMO between 2013 and 2015 were searched. Numbers of patients, types of chemotherapy, patient baseline, proportion of patients receiving post-Cx (post-Cx%), median progression-free survival (mPFS), and median overall survival (mOS) of each treatment arm were surveyed; trials not reporting these parameters were excluded. Median post-progression survival (mPPS) was calculated as the difference between mOS and mPFS. Weighted Spearman's correlation coefficients between post-Cx% and survival outcomes (mOS and mPPS) were calculated. The effect of post-Cx% on survival outcomes adjusted for the types of chemotherapy and patient characteristics was evaluated by meta-regression. Overall, 25 phase III trials of AGC were selected: 15 trials with 31 arms for 1st-Cx, and 10 trials with 16 arms for 2nd-Cx. Weighted Spearman's correlation coefficients for post-Cx% and mOS/mPPS were 0.520/0.739 for 1st-Cx, and 0.767/0.823 for 2nd-Cx. Meta-regression analyses adjusting for types of chemotherapy, age, and PS showed that a 10% increase in post-Cx% was associated with prolongation of mOS by 1.033 months for 1st-Cx and 0.344 months for 2nd-Cx. Post-Cx% both after 1st-Cx and 2nd-Cx were correlated with mOS/mPPS, suggesting a survival benefit of 3rd-Cx in addition to that of 2nd-Cx for AGC. |
X Demographics
The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Saudi Arabia | 6 | 38% |
| Chile | 2 | 13% |
| Unknown | 8 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 88% |
| Practitioners (doctors, other healthcare professionals) | 2 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 25 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 20% |
| Student > Postgraduate | 3 | 12% |
| Lecturer | 2 | 8% |
| Other | 2 | 8% |
| Researcher | 2 | 8% |
| Other | 3 | 12% |
| Unknown | 8 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 52% |
| Business, Management and Accounting | 2 | 8% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Nursing and Health Professions | 1 | 4% |
| Unknown | 8 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 September 2018.
All research outputs
#3,131,808
of 25,368,786 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#104
of 2,562 outputs
Outputs of similar age
#62,503
of 344,173 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#2
of 30 outputs
Altmetric has tracked 25,368,786 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,562 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,173 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.